*Is Cerebral Vasomotor Reactivity impaired in Idiopathic Parkinson's Disease?*

Martha F Hanby BSc, MB ChB, MRes [a*], Ronney B Panerai BSc, MSc, PhD [a, b], Thompson G Robinson BSc, MB ChB, MD [a, b] and Victoria J Haunton BM MD [a, b]

a. University of Leicester, Department of Cardiovascular Sciences, Leicester, LE2 7LX, UK.
b. Leicester NIHR Biomedical Research Unit for Cardiovascular Disease, Glenfield Hospital, Leicester, LE3 9QP, UK.

Corresponding Author:

Dr Martha F Hanby,

Department of Clinical Neurophysiology, Floor N, Royal Hallamshire Hospital, Sheffield, United Kingdom

Tel: 00 44 114 271 2400

Email: marthahanby@hotmail.com

***Word Count***:

***Key words***: dopamine; hypocapnia; idiopathic Parkinson's disease; Transcranial Doppler; vasomotor reactivity

**Abstract**

The ability of a blood vessel to change diameter in response to a change in carbon dioxide concentration is often referred to as vasomotor reactivity. The current study aimed to determine whether vasomotor reactivity is impaired in patients with idiopathic Parkinson's Disease in comparison to healthy controls. Transcranial Doppler was used to measure cerebral blood flow velocity in the middle cerebral arteries at baseline and in response to a hypocapnic stimulus in 40 patients with idiopathic Parkinson's disease and 50 healthy controls. Vasomotor reactivity, assessed under hypocapnic conditions, is not impaired in patients with idiopathic Parkinson's disease in comparison to healthy controls.

*1. Introduction*

Vasomotor reactivity (VMR) is the ability of cerebral blood flow (CBF) to change in response to changes in arterial partial pressure of $CO_2$ ($PaCO_2$) [1]. Hypocapnia induces cerebral vasoconstriction, whilst hypercapnia induces cerebral vasodilatation. Such changes in cerebral blood vessel diameter are largely determined by extracellular pH ($[H^+]$) [2] but the autonomic nervous system has also been implicated [3]. Autonomic dysfunction has been reported in up to 58% of patients with idiopathic Parkinson's disease (IPD) [4].

Dynamic cerebral autoregulation (dCA) refers to how spontaneous fluctuations in arterial blood pressure (ABP) can be measured alongside beat-to-beat measurement of CBF velocity (CBFV). Parameters that assess the integrity of dCA include Cerebrovascular Resistance (CVR), Critical Closing Pressure (CrCP), Resistance Area Product (RAP) [5] and Autoregulatory Index (ARI) [6]. Under hypocapnic conditions, dCA has been shown to improve in healthy subjects [7, 8].

The current study aims to address three questions: (1) Is VMR impaired in patients with IPD in comparison to age-matched healthy controls (HC)? (2) Under hypocapnic conditions, do measures of dCA: CVR, CrCP, RAP and ARI show significant increases of the same magnitude, in both HC and

IPD patients? (3) Does medication status (ON vs. OFF) affect either VMR or dCA measures under hypocapnic conditions?

## 2. Methods

Ethical approval for the study was obtained from the Northampton Research Ethics Committee, United Kingdom (reference 11/EM/0369). All participants were over 18 years of age and gave written informed consent.

IPD patients were recruited from specialist clinics within the University Hospitals of Leicester NHS trust, and by direct invitation facilitated by Parkinson's Disease UK. All had received a diagnosis of IPD according to the UK PD Brain Bank criteria [9] from a specialist physician. Age-matched HC were recruited from the local area or from spouses of patients with IPD. Exclusion criteria were: diabetes mellitus; dementia; peripheral neuropathy; ischaemic heart disease and cerebrovascular disease. IPD patients with a dependence on anti-parkinsonian medications for a safe swallow (ensuring no risk of aspiration during their OFF scan), or previously treated with deep brain stimulation were also excluded.

Baseline demographics were collected from all participants including Hoehn and Yahr stage [10] and Unified Parkinson's disease rating scale (UPDRS) scores [11].

All measurements were undertaken in a cardiovascular laboratory, free from distraction and of controlled temperature (20-24$^{o}$C). Participants were asked to refrain from large meals, caffeine, alcohol, cigarettes and strenuous exercise for four hours prior to measurements. HC underwent the TCD scan once, whilst patients with IPD undertook the assessments twice: ON and OFF dopaminergic medication. They were asked to abstain from their PD medications for either 12 or 24 hours depending on the preparation.

Participants lay supine on a couch. Heart rate (HR), ABP and end-tidal $CO_2$ (ETCO$_2$) were continuously monitored with the use of a 3-lead ECG, Finometer® (Finapres Medical Systems, Amsterdam, The Netherlands), and nasal capnography (Capnocheck Plus), respectively. Bilateral insonation of the middle cerebral artery (MCA) was performed using TCD (Viasys Companion III, Viasys Health Care) with a 2MHz probe.

The respiratory manouevre consisted of 60 s of rest; 90 s of the participant nose-breathing in time with an electronic metronome which for the first 30 s gradually increased in frequency to achieve a respiratory rate of 25 breaths per minute that was subsequently maintained for a further 60 s; 120 s of rest. During the recording the internal plethysmography servo-adjust of the Finapres®/Portapres/Finometer was switched off, and a manual ABP calibration was taken at the commencement of the recording by a brachial sphygmomanometer (OMRON 705IT). Data were edited using in-house customized software. The ABP signal was calibrated at the start of each recording. The R-R interval was automatically marked using the ECG trace. Mean ABP (MAP) and CBFV were calculated for each cardiac cycle and $ETCO_2$ was synchronized to the end of each cardiac cycle. CVR, CrCP and RAP for each cardiac cycle were calculated using the first harmonic method [5]. Beat-to-beat data were then spline interpolated and re-sampled at 5 samples/s to create time-series with a uniform time base. An auto-regressive moving average technique [8] was then used to model the dynamic relationship between MAP and CBFV leading to time-varying estimates of ARI as described previously [7]. Changes in $ETCO_2$ following hyperventilation were marked by visual inspection. Values of population coherent averages and standard deviations were obtained for each variable at each time sample, synchronized by the beginning of the hyperventilation manouevre.

Paired and un-paired t-tests were used to compare baseline peripheral and central haemodynamics between groups. The effects of hyperventilation on peripheral (HR, MAP) and cerebral haemodynamic parameters (CBFV, CVR, CrCP, RAP, ARI) within each group (IPD ON, IPD OFF, HC) were measured as the difference in their mean values obtained during a 12 s period during hyperventilation and an 18 s period within the 60 s of rest prior to the onset of hyperventilation by paired t-tests. The 18 s period within the 60 s of rest was used to calculate all baseline peripheral and central haemodynamics.

IPD is a disease of laterality; therefore all cerebral haemodynamic data were calculated for both onset and other brain hemisphere in each medication state. For HC, cerebral haemodynamic data were calculated for left and right hemispheres. When no significant difference was found on paired t-tests between the values obtained for the sides, the mean value was taken and used in subsequent analyses.

VMR was calculated for each participant group (IPD ON, IPD OFF, HC) both in terms of absolute differences:

$$\text{VMR (cm/mmHg.s)} = (\text{CBFV}_H - \text{CBFV}_B)/ (\text{ETCO}_{2\,H} - \text{ETCO}_{2\,B})$$

and relative differences:

$$\text{VMR (\%/mmHg)} = (\text{CBFV}_H - \text{CBFV}_B/\text{CBFV}_B)/ (\text{ETCO}_{2\,H} - \text{ETCO}_{2\,B})$$

$_B$ = baseline; $_H$ = hyperventilation

Statistical significance was set at $p < 0.05$. Bonferroni corrections were applied to multiple comparisons.

## 3. Results

40 IPD patients and 50 HC completed the full protocol. The two groups were well matched with respect to baseline demographics (See Supplementary Table 1). Mean disease duration of IPD was 7.5 (17.3) years, and median HY score was 1.5 (1-2.5; 0-3). Median levodopa equivalent daily dose was 545mg (300-760; 150-1315). IPD ON patients had a median total UPDRS score of 34 (24-40; 12-61). IPD patients OFF medication had significantly higher Motor (Part III) UPDRS scores than whilst ON medications (20.5 vs. 14, $p < 0.0001$, respectively).

Baseline peripheral and central haemodynamic parameters were no different between any of the three groups (Table 1).

Hyperventilation significantly increased HR and reduced $ETCO_2$ in all three groups. Only in HC did hyperventilation cause a significant reduction in MAP (90.4 (11.4) vs. 89.0 (10.9), $p = 0.02$). In terms of absolute differences between the three groups, the only significant difference was found between IPD ON and HC, where the reduction in $ETCO_2$ was significantly greater in HC than IPD ON patients (8.02 (3.3) vs. 6.33 (3.0) mmHg, $p = 0.01$) (Figure 1).

The only significant difference in cerebral haemodynamics between hemispheres was that of ARI values in IPD ON patients under hypocapnic conditions. Onset hemisphere was found to have a significantly higher mean ARI value than the other hemisphere (5.49 (1.61) vs. 4.95 (1.76), $p < 0.025$). No significant differences between hemispheres in all other cerebral haemodynamic parameters (CBFV; CVR; CrCP; RAP) within each of the three groups were seen, under either normocapnic or hypocapnic conditions. Consequently mean hemisphere values were taken for all cerebral

haemodynamic parameters in each of the three groups when comparing baseline to hyperventilation values, except for IPD ON patients where ARI values between baseline and hyperventilation were compared within the individual hemispheres.

Effects of hyperventilation on cerebral haemodynamic parameters were the same in all three groups. Hyperventilation resulted in a significant reduction in CBFV ($p < 0.0001$) but significant increases in CVR ($p < 0.0001$), CrCP ($p < 0.0001$), RAP ($p < 0.0001$) and ARI ($p < 0.001$) (Figure 1, Supplementary Table 2).

VMR was not significantly different between the three groups. Comparisons between both IPD ON and HC (1.17 (1.11) vs. 1.50 (0.78) cm/mmHg.s, $p = 0.12$) and IPD OFF and HC (1.35 (1.21) vs. 1.50 (0.78) cm/mmHg.s, $p = 0.52$) were not significant. Again, dopaminergic status was not found to have a significant effect (1.17 (1.11) vs. 1.35 (1.21) cm/mmHg.s, $p = 0.48$). Calculation of the % change in CBFV (cm/s) per mmHg change in $ETCO_2$ between baseline and hyperventilation, in each of the 3 groups, was also not found to be significant (IPD ON vs. HC: 2.5 (2.6) vs. 2.9 (1.0)%/mmHg, $p = 0.159$; IPD OFF vs. HC: 2.8 (3.0) vs. 2.9 (1.0)%/mmHg, $p = 0.442$; IPD ON vs. IPD OFF: 2.5 (2.6) vs. 2.8 (3.0)%/mmHg, $p = 0.640$).

*4. Discussion*

This study demonstrates that dCA and measures of VMR, assessed under hypocapnic conditions, do not significantly differ between HC and patients with IPD, irrespective of medication status.

To date there have been five studies investigating VMR in IPD [12-16]. Of these five studies, only one study found IPD participants to have impaired VMR in comparison to age-matched HC [16], two studies failed to include a comparative HC group [14, 15], whilst the latest studies using novel MRI techniques concurred with the findings of our study [12-13]. Importantly, these latter studies boasted larger participant numbers and more definite measures of monitoring $ETCO_2$ levels.

To allow more in-depth interpretation of our results, we also studied the temporal patterns of CrCP, RAP and ARI as shown in Fig. 1. With the onset of hypocapnia (Fig. 1.A), ABP shows a marked peak in all three groups, which is transmitted to CBFV (Fig. 1.C). This marked change in ABP is likely to result from sympathetic stimulation caused by the stress of breathing in time with the metronome. The delayed peak in RAP (Fig. 1.E) is likely to represent the myogenic response to the ABP peak and,

together with the rise in CrCP, causes the rapid decrease of CBFV (Fig. 1.C). Of considerable interest, the rise in ARI with hypocapnia (Fig. 1.F) is delayed by approximately 30 s. One possible explanation is that dCA is initially depressed by the sympathetic stimulation associated with the alert reaction of hyperventilation [8]. After 60 s, the relatively small surge in ABP is manifest as a much steeper rise in RAP, possibly due to the much increased effectiveness of dCA as indicated by the higher values of ARI in Fig. 1.F. This secondary rise in RAP explains the continuing reduction in CBFV (Fig. 1.C), since CrCP remains relatively constant during this phase (Fig. 1.D). Although none of these cerebrovascular parameters showed significant differences due to IPD or dopamine, it is important to take into account the complex interactions induced by hypocapnia in future studies to allow a better understanding of the contribution of different co-variates.

A limitation of the current study is not assessing VMR under hypercapnic conditions, which would enable assessment of both the vasomotor range and vasodilatation reserve in patients with IPD and HC. Due to physiological adaptations of vascular beds, in diseased states resting perfusion and vasoconstriction are typically found to be preserved states whilst vasodilatation reserve is not. However, in conclusion, our study reports that VMR, when assessed under hypocapnic conditions, in patients with IPD, irrespective of medication status, is not impaired in comparison to HC. Future studies should also determine the effects of hypercapnia on VMR in patients with IPD in comparison to HC.

## 5. *References:*

1    Markwalder TM, Grolimund P, Seiler RW, Roth F, Aaslid R. (1984) Dependency of blood flow velocity in the middle cerebral artery on end-tidal carbon dioxide partial pressure – A transcranial ultrasound Doppler study. J Cereb Blood Flow Metab. 4: 368-72.

2    Edvinsson L, Sercombe R. (1976) Influence of pH and $PaCO_2$ on alpha-receptor mediated contraction in brain vessels. Acta Physiol. Scand. 97: 325-331.

3    Pebbles KC, Ball OG, MacRae BA et al. (2012) Sympathetic regulation of the human cerebrovascular response to carbon dioxide. Journal of Applied Physiology. 113: 700-706.

4    Low PA. (2008) Prevalence of orthostatic hypotension. Clin Auton Res. 18: 8-13.

5    Panerai RB. (2003) The critical closing pressure of the cerebral circulation. Med Eng Phys. 25: 621-632.

6    Tiecks FP, Lam AM, Aaslid R, Newell DW. (1995) Comparison on static and dynamic cerebral autoregulation measurements. Stroke. 26: 1014-1019.

7    Carrera E, Lee LK, Giannopoulos S, Marshall RS. (2009) Cerebrovascular reactivity and cerebral autoregulation in normal subjects. J Neurol Sci. 285:191-194.

8    Dineen NE, Brodie FG, Robinson TG, Panerai RB. (2010) Continuous estimates of dynamic cerebral autoregulation during transient hypocapnia or hypercapnia. J Appl Physiol. 108: 604-613.

9    Douglas J, Oliver E, Gilman S. (1999) Diagnostic criteria for Parkinson's disease. Arch Neurol. 56: 33-39.

10   Hoehn M, Yahr M. (1967) Parkinsonism: onset, progression and mortality. Neurology. 17: 427-442.

11   Fahr S, Elton RL. (1987) UPDRS program members. Unified Parkinson's Disease Rating Scale. In: Fahr S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinson's disease. Vol 2, Florham Park, NJ: Macmillan Healthcare Information, pp 153-163.

12   Krainik A, Maillet A, Fleury V et al. (2013) Levodopa does not change cerebral vasoreactivity in Parkinson's Disease. Mov Disord. 28: 469-475.

13   Al-Bachari S, Parkes LM, Vidyasagar R et al. (2014) Arterial spin labelling reveals prolonged arterial arrival time in idiopathic Parkinson's disease. Neuroimage 6: 1-8.

14   Gurevich T, Gur AY, Bornstein NM, Giladi N, Korczyn AD. (2006) Cerebral vasomotor reactivity in Parkinson's disease, multiple system atrophy and pure autonomic failure. J Neurol Sci. 243: 57-60.

15   Zamani B, Mehrnoush M, Fereshtehnejad SM, Rohani M. (2011) Evaluation of cerebral vasomotor reactivity in Parkinson's disease: Is there any association with orthostatic hypotension. Clin Neurol Neurosurg. 113: 368-372.

16   Hamdy MM, Sadallal HM, Elsalamawy DH. (2012) The study of vasoreactivity of the cerebral vessels in patients with Parkinson's disease. Egyptian J Neurol Psych Neurosurg. 49: 353-357.